StockCIK 1228627
Opus Genetics, Inc. (IRD): Insider Trades and Fund Holdings
In the past 12 months, Opus Genetics, Inc. insiders reported 0 open-market purchases worth $0 and 6 sales worth $3.10M; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$3.10MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 27, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 27 | Benjamin R. YerxaPresident | ▼ SELL | $117K |
| Oct 27 | Robert E. GagnonCFO | ▼ SELL10b5-1 | $50K |
| Oct 27 | George MagrathCEO | ▼ SELL | $34K |
| Oct 27 | Joseph K. SchachleCOO | ▼ SELL | $17K |
| Oct 2 | Foundation Fighting Blindness Retinal Degeneration FundDirector | ▼ SELL | $2.76M |
| Sep 8 | Robert E. GagnonCFO | ▼ SELL | $127K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Benjamin R. Yerxa | President | 0 | $0 | 1 | $117K |
| Robert E. Gagnon | CFO | 0 | $0 | 2 | $177K |
| George Magrath | CEO | 0 | $0 | 1 | $34K |
| Joseph K. Schachle | COO | 0 | $0 | 1 | $17K |
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | 0 | $0 | 1 | $2.76M |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report IRD
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 0 | $0 | ▼ Sold out |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →